Gelatinous Capsules of β-Lapachone for Anti-cancer Therapies

被引:0
|
作者
Presmich, Geisiane M. A. [1 ]
Rolim, Larissa A. [1 ]
Medeiros, Flavia P. M. [1 ,3 ]
Albuquerque, Miracy M. [2 ]
Rolim-Neto, Pedro J. [1 ]
机构
[1] Univ Fed Pernambuco, Lab Tecnol Medicamentos, Dept Ciencias Farmaceut, BR-50740521 Recife, PE, Brazil
[2] Univ Fed Pernambuco, NCQMC, BR-50740521 Recife, PE, Brazil
[3] Lab Farmaceut Estado Pernantbuco LAFEPE Largo de, BR-52171010 Recife, PE, Brazil
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2010年 / 29卷 / 05期
关键词
beta-lapachone; soft gelatinous capsules and hard; stability; PROSTATE-CANCER CELLS; MEDIATED APOPTOSIS; DERIVATIVES; INHIBITION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
"Gelatinous Capsules of beta-Lapachone for Anti-cancer Therapies". beta-lapachone is a natural ortonaftoquinona of ipe purple growing mainly in Brazil, also obtained by the process of semi-synthesis of its isomer lapachol. It is a simple plant product that has demonstrated excellent potential in antineoplastic studies in albino rats, mice and cell cultures. Works by a particular mechanism of apoptosis against various types of cancer, especially some strains of prostate refractory to conventional treatments. It has low solubility in water, the development of a pharmaceutical form the basis of beta-lapachone providing favorable bioavailability is a key point for the continuity of research with this asset. Hard gelatine capsules containing 250 mg of beta-lapachone and soft gelatine capsules containing 30 mg beta-lapachone were developed. Due to the crystalline form and character of lipophilic beta-lapachone, the hard gelatin capsules did not show acceptable levels of dissolution, however, the soft gelatinous capsules showed satisfactory results for continuation of studies in this active.
引用
收藏
页码:674 / 680
页数:7
相关论文
共 50 条
  • [41] A mixed methods analysis of the monitoring of oral anti-cancer therapies
    O'Mahony, Cian
    Murphy, Kevin D.
    Byrne, Stephen
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2021, 54
  • [42] CAR macrophages tuning the immune symphony of anti-cancer therapies
    Paasch, Daniela
    Lachmann, Nico
    CELL STEM CELL, 2024, 31 (06) : 791 - 793
  • [43] Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies
    Lukow, Devon A.
    Sausville, Erin L.
    Suri, Pavit
    Chunduri, Narendra Kumar
    Wieland, Angela
    Leu, Justin
    Smith, Joan C.
    Girish, Vishruth
    Kumar, Ankith A.
    Kendall, Jude
    Wang, Zihua
    Storchova, Zuzana
    Sheltzer, Jason M.
    DEVELOPMENTAL CELL, 2021, 56 (17) : 2427 - +
  • [44] Ocular side effects of novel anti-cancer biological therapies
    Vishnevskia-Dai, Vicktoria
    Rozner, Lihi
    Berger, Raanan
    Jaron, Ziv
    Elyashiv, Sivan
    Markel, Gal
    Zloto, Ofira
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [45] Ocular side effects of novel anti-cancer biological therapies
    Vicktoria Vishnevskia-Dai
    Lihi Rozner
    Raanan Berger
    Ziv Jaron
    Sivan Elyashiv
    Gal Markel
    Ofira Zloto
    Scientific Reports, 11
  • [46] Defective cell cycle checkpoints as targets for anti-cancer therapies
    Gabrielli, Brian
    Brooks, Kelly
    Pavey, Sandra
    FRONTIERS IN PHARMACOLOGY, 2012, 3
  • [47] Mitosis-targeted anti-cancer therapies: where they stand
    Chan, K-S
    Koh, C-G
    Li, H-Y
    CELL DEATH & DISEASE, 2012, 3 : e411 - e411
  • [48] Targeting immuno-metabolism to improve anti-cancer therapies
    Beezhold, Kevin
    Byersdorfer, Craig A.
    CANCER LETTERS, 2018, 414 : 127 - 135
  • [49] Mitosis-targeted anti-cancer therapies: where they stand
    K-S Chan
    C-G Koh
    H-Y Li
    Cell Death & Disease, 2012, 3 : e411 - e411
  • [50] Inorganic Nanomaterials Used in Anti-Cancer Therapies:Further Developments
    Dlugosz, Olga
    Matyjasik, Wiktoria
    Hodacka, Gabriela
    Szostak, Krzysztof
    Matysik, Julia
    Krawczyk, Patrycja
    Piasek, Anna
    Pulit-Prociak, Jolanta
    Banach, Marcin
    NANOMATERIALS, 2023, 13 (06)